Johns Hopkins HIV Guide
Sofosbuvir
INDICATIONS
FDA
FDA
- Treatment of HCV genotype 1, 2, 3, or 4 as a component of a combination antiviral treatment regimen
- Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection
- Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotypes 5 and 6
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 3, 2023
Citation
Auwaerter, Paul G, and Janessa M Smith. "Sofosbuvir." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545245/all/Sofosbuvir.
Auwaerter PG, Smith JM. Sofosbuvir. Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545245/all/Sofosbuvir. Accessed December 6, 2023.
Auwaerter, P. G., & Smith, J. M. (2023). Sofosbuvir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545245/all/Sofosbuvir
Auwaerter PG, Smith JM. Sofosbuvir [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 December 06]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545245/all/Sofosbuvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sofosbuvir
ID - 545245
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa,Pharm.D. BCPS
Y1 - 2023/08/03/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545245/all/Sofosbuvir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
